附件 10.16
利思特生物科技控股有限公司
薪酬 退款政策
一、目的和範圍
董事會(“董事會”)認為，創建和保持一種強調誠信和責任的文化，並 加強公司的績效薪酬理念，符合利士特生物科技控股有限公司(“公司”)及其股東的最佳利益。因此，董事會採納了這一薪酬追回政策(“政策”)，規定在發生觸發事件(定義見下文)的情況下，向本公司的 高管追回錯誤授予的獎勵薪酬。
二、行政管理
本政策旨在遵守美國證券交易法第10D條、規則10D-1、納斯達克上市規則第5608條和其他規定、規則 及其下的美國證券交易委員會(下稱“美國證券交易委員會”)的指導意見，以及相關證券法規和公司普通股上市所在證券交易所或協會的法規。本政策由董事會薪酬委員會(“委員會”)管理。
委員會作出的任何決定均為終局決定，具有約束力。此外，公司應根據《交易法》第10D條和美國證券交易委員會頒佈的第10D-1條，提交與 本政策有關的所有披露，包括適用的《美國證券交易委員會》法規所要求的披露，以及公司證券所在的國家證券交易所採用的任何規則或標準所要求的披露。委員會特此有權強制執行本政策的條款和條件，並使用其認為適當的任何和所有公司資源來收回受本政策約束的任何額外獎勵 補償。
三. 涵蓋高管
本政策適用於本公司現任和前任高管，由委員會根據交易法10D節、美國證券交易委員會頒佈的規則10D-1以及公司證券在其上市的國家證券交易所的上市標準確定。
IV. 根據本政策觸發退還的事件
董事會或委員會將被要求追回任何承保高管在緊接本公司被視為(根據緊隨其後的句子確定的 被要求為其財務報表編制會計重報的日期)之前的三(3)個完整會計年度(連同因公司過渡到不同會計年度計量日期而導致的不到九(9)個月的間歇性會計存根(S))期間收到的任何超額激勵薪酬。就上一句而言，本公司被視為須於以下日期就其財務報表編制會計重述：(A)董事會或委員會或獲授權採取該等行動的本公司高級人員(如董事會無須採取行動)得出或理應得出結論認為本公司須編制備註會計重述的日期；或(B)法院、監管機構或其他法定授權機構指示本公司編制備考會計重述的日期(“觸發事件”)。
| 1 |
V. 超額激勵薪酬：待追回的金額
應追回的激勵性薪酬金額應為被保險人 收到的激勵性薪酬超出被保險人本應收到的激勵性薪酬的數額，如果按照委員會所確定的重述數額計算此類激勵性薪酬的金額。就本政策而言，激勵薪酬 應被視為在達到任何適用的財務報告措施的會計年度(或根據或基於授予、賺取或授予激勵薪酬 的任何財務報告措施的完成情況)全部或部分收到，即使此類激勵薪酬的支付、歸屬或授予發生在該會計年度的 結束之後。根據本政策要求退還的金額將按税前計算。
具體理解是，如果會計重述對收到的激勵性補償金額的影響不能直接從會計重述中的信息計算(例如，如果重述對公司股價的影響不清楚)，則該超額激勵性補償應根據 委員會對會計重述對收到激勵性補償的股價或股東總回報的影響的合理估計來確定。公司應保存確定超額金額的文件，並 根據需要向納斯達克股票市場(“納斯達克”)提供文件。
六. 恢復方法
委員會將自行決定收回本協議項下超額激勵報酬的方法，該方法可 包括但不限於：
| a. | 要求報銷以前支付的現金激勵薪酬； | |
| b. | 尋求追回因授予、行使、結算、出售、轉讓或以其他方式處置任何股權獎勵而獲得的任何收益； | |
| c. | 在適用的範圍內，從公司以其他方式欠或將欠受保高管的任何補償中抵消 已收回的金額； | |
| d. | 取消 尚未行使的已歸屬或未歸屬股權獎勵；及/或 | |
| e. | 以 委員會決定的法律允許的任何其他補救和恢復行動。 |
| 2 |
七. 不切實際
The Committee shall recover any excess Incentive Compensation in accordance with this Policy unless such recovery would be impracticable, as determined by the Committee in accordance with Rule 10D-1 of the Exchange Act and the listing standards of the stock exchange or association on which the Company’s securities are listed. It is specifically understood that recovery will only be deemed impractical if: (A) the direct expense paid to a third party to assist in enforcing the policy would exceed the amount to be recovered (before concluding that it would be impracticable to recover any amount of erroneously awarded Incentive Compensation based on the expense of enforcement, the Committee shall make a reasonable attempt to recover such erroneously awarded Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the stock exchange or association on which the Company’s common shares are trading); (B) recovery would violate home country law where that law was adopted prior to November 28, 2022 (before concluding that it would be impracticable to recover any amount of erroneously awarded Incentive Compensation based on violation of home country law, the Committee shall obtain an opinion of home country legal counsel, acceptable to the applicable stock exchange or association on which Company’s common shares are listed, that recovery would result in such a violation, and must provide such opinion to Nasdaq as may be required); or (C) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the registrant, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a), and the regulations promulgated thereunder.
八. 其他退款權利；確認
委員會可要求，在生效日期 或之後簽訂的任何僱傭協議、股權獎勵協議或類似協議，作為授予其項下任何利益的條件，應要求受保人同意遵守本 政策的條款。本政策項下的任何收回權利是對 根據任何僱傭協議、股權獎勵協議或類似 協議中的任何類似政策條款以及公司可用的任何其他法律補救措施的補充，而不是替代這些補救措施或收回權利。公司應發出通知，並尋求每名受保人對 本政策的書面確認； 提供，未能提供此類通知或獲得此類確認不會對本政策的適用性或可執行性產生影響。
九. 無賠償或公司支付保險
公司不應就任何超出獎勵報酬的損失向任何受保人進行賠償。此外，公司將 禁止向投保經理支付或報銷為支付任何潛在 賠償義務而購買的任何第三方保險的保費。
| 3 |
X. 修訂和終止；解釋
The Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary to reflect and comply with further regulations, rules and guidance of the SEC, and rules of the stock exchange or association on which Company’s common shares are listed. The Board may terminate this Policy at any time. The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. This Policy is designed and intended be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act, Rule 10D-1 and other regulations, rules and guidance of the SEC thereunder, and related securities regulations and regulations of the stock exchange or association on which Company’s common shares are listed. To the extent of any inconsistency between this Policy and such regulations, rules and guidance, such regulations, rules and guidance shall control and this Policy shall be deemed amended to incorporate such regulations, rules and guidance unless the Board or the Committee shall expressly determine otherwise. This Policy shall be applicable, binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives, to the fullest extent of the law.
Xi. 定義
就本政策而言，下列術語應具有以下含義：
| 1. | “董事會”指本公司的董事會。 | |
| 2. | "公司" 指Lixte Biotechnology Holdings，Inc. | |
| 3. | A “Covered Accounting Restatement” is any accounting restatement of the Company’s financial statements due to the Company’s material noncompliance with any financial reporting requirement under U.S. securities laws. A Covered Accounting Restatement includes any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (commonly referred to as “Big R” restatements), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (commonly referred to as “little r” restatements). A Covered Accounting Restatement does not include an out-of-period adjustment when the error is immaterial to the previously issued financial statements, and the correction of the error is also immaterial to the current period; a permitted retrospective application of a change in accounting principle or a required adoption of a new accounting policy; retrospective revision to reportable segment information due to a change in the structure of an issuer’s internal organization; retrospective reclassification due to a discontinued operation; retrospective application of a change in reporting entity, such as from a reverse recapitalization or reorganization of entities under common control; and retrospective revision for stock splits, reverse stock splits, stock dividends or distributions, or other changes in capital structure. |
| 4 |
| 4. | “承保高管”是指任何符合以下條件的人員： |
| a. | 是否已收到適用的獎勵薪酬： |
| i. | 在三年的恢復期內；以及 | |
| 二、 | 在開始擔任行政幹事後；以及 |
| b. | 是否在績效期間的任何時間擔任高管以獲得此類激勵性薪酬 。 |
| 5. | "有效 日期”指董事會採納政策的日期。 | |
| 6. | “證券交易法”係指修訂後的1934年證券交易法。 | |
| 7. | “Executive Officer(s)” means an “executive officer” as defined in Exchange Act Rule 10D-1(d), and includes any person who is the Company’s Chief Executive Officer, President, Principal Financial Officer, Principal Accounting Officer (or if there is no such financial or accounting officer, the controller), any Vice President of the issuer in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company (with any executive officers of the Company’s parent or subsidiaries being deemed Covered Executives of the Company if they perform such policy making functions for the Company). All executive officers of the Company identified by the Board pursuant to 17 CFR 229.401(b) shall be deemed “Executive Officers”. | |
| 8. | "金融 報告措施"是指根據 確定和提交的任何措施 與編制公司財務報表所使用的會計原則， 以及全部或部分源自此類措施的任何措施，包括股價 和股東總回報，還包括但不限於財務報告 為《外匯法條例》目的採取的"非GAAP財務措施"等措施 G和17 CFR 229.10，以及非非GAAP指標的其他指標、指標和比率， 例如同店銷售。《財務報告辦法》可以或可以不包括在備案文件中 與美國證券交易委員會，並可能在公司財務報表之外提交，例如 如管理層對財務狀況和經營結果的討論和分析 或性能曲線圖。財務報告措施包括但不限於： |
| a. | 公司 股價 | |
| b. | 合計 市值 | |
| c. | 合計 股東回報 | |
| d. | 收入 | |
| e. | 操作 盈利能力 | |
| f. | 淨收入 | |
| g. | 收益 扣除利息、税項、折舊及攤銷前（EBITDA） | |
| h. | 流動性 諸如營運資金或營運現金流等指標 | |
| i. | 返回 投資資本回報率或資產回報率等指標 |
| 5 |
| j. | 收益 例如每股收益 | |
| k. | 其他 適用於公司研發和臨牀的操作措施 審判活動 |
| 9. | “Incentive Compensation” means any compensation which (A) was approved, awarded or granted to, or earned by a Covered Executive while the Company has a class of securities listed on a national securities exchange or a national securities association, and (B) approved, awarded or granted to, or earned by the Covered Executive following on or after the Effective Date (including any award under any long-term or short-term incentive compensation plan of the Company, including any other short-term or long-term cash or equity incentive award or any other payment) that, in each case, is granted, earned, or vested based wholly or in part upon the attainment of any Financial Reporting Measure (i.e., any measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measure that is derived wholly or in part from such measures, including share price and total shareholder return). Incentive Compensation may include (but is not limited to) any of the following: |
| a. | 年度 獎金和其他短期和長期現金獎勵 | |
| b. | 股票 期權 | |
| c. | 股票 增值權利 | |
| d. | 受限的 股 | |
| e. | 受限的 個共享單位 | |
| f. | 性能 個共享 | |
| g. | 性能 個單位 |
| 6 |